SignalXSignalX

IBRX ImmunityBio, Inc.

8-K Current Report
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)
ImmunityBio, Inc. Overview

ImmunityBio, Inc. (IBRX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 financial results released Feb 23, 2026; details in Exhibit 99.1
  • • Filing covers period ending Dec 31, 2025, including balance sheet position as of that date
+1 more insights

Get deeper insights on ImmunityBio, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.